<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984434</url>
  </required_header>
  <id_info>
    <org_study_id>NTP-F182112-001</org_study_id>
    <nct_id>NCT04984434</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A First-in-human, Open-label, Multiple Center Phase 1 Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetic, Immunogenicity, and Preliminary Efficacy of F182112 in Patients With Relapsed or Refractory Multiple Myeloma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong New Time Pharmaceutical Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong New Time Pharmaceutical Co., LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a Multiple center, Open-label, dose escalation Phase Ⅰ clinical study. The&#xD;
      purpose is to evaluate the safety and tolerability of F182112 when infused intravenously (IV)&#xD;
      and determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of&#xD;
      F182112 when infused IV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a&#xD;
      recommended phase 2 dose regimen (RP2DR) of F182112 as monotherapy in patients with relapsed&#xD;
      or refractory multiple myeloma (MM).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLTs</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Maximum Tolerated Dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Preliminary Antitumor Activity of F182112 at the RP2D(s) in Part 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>To evaluate the duration from the first dose to death of patients with MM for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Evaluation of the efficacy of F182112 in patients with MM on progression-free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Objective remission rate was used to evaluate the efficacy of F182112 injection in patients with MM.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Minimal Residual Disease (MRD) Negative Rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Minimal Residual Disease (MRD) Negative Rate</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Experimental: Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F182112</intervention_name>
    <description>Eight dose cohorts: 0.01, 0.1, 0.3, 1, 3, 10, 20 and 30 μg/kg) d1 treat every weeks.</description>
    <arm_group_label>Experimental: Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Willing and able to provide signed and dated informed consent prior to any&#xD;
             study-related procedures and willing and able to comply with all study procedures;&#xD;
&#xD;
             2) Male or female ≥ 18 years;&#xD;
&#xD;
             3) Patient has a history of multiple myeloma with relapsed and refractory disease, and&#xD;
             must:&#xD;
&#xD;
               1. Relapsed after an autologous stem cell transplant (ASCT), or not suitable for&#xD;
                  ASCT;&#xD;
&#xD;
               2. Must have received at least 2 prior multiple myeloma treatment regimens (not&#xD;
                  including autologous stem cell transplant) including a proteasome inhibitor, an&#xD;
                  immunomodulatory agent;&#xD;
&#xD;
                  4) ECOG of 0-2;&#xD;
&#xD;
                  5) Patients must have measurable disease, including at least one of the criteria&#xD;
                  below:&#xD;
&#xD;
               1. M-protein ≥ 0.5 g/dL by SPEP/immunofixation or&#xD;
&#xD;
               2. ≥ 200 mg/24 hours urine collection by UPEP or&#xD;
&#xD;
               3. Serum free light chain (FLC) levels &gt; 100 mg/L (milligrams/liter involved light&#xD;
                  chain) and an abnormal kappa/lambda (κ/λ) ratio in patients without detectable&#xD;
                  serum or urine M-protein;&#xD;
&#xD;
                  6) Adequate hepatic function as evidenced by meeting all the following&#xD;
                  requirements:&#xD;
&#xD;
               1. Blood routine: absolute neutrophil count (ANC) ≥ 1.0×109/L, hemoglobin (Hb)&#xD;
                  ≥70g/L, Platelet ≥ 50×109/L;&#xD;
&#xD;
               2. Liver function: total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine&#xD;
                  aminotransferase (ALT) ≤ 2.5 × ULN, Aspartate aminotransferase (AST) ≤ 2.5 × ULN;&#xD;
&#xD;
               3. Renal function: calculated creatinine clearance (CrCL) ≥ 30 mL/min&#xD;
                  (Cockroft-Gault Equation).&#xD;
&#xD;
                  7) Recovery to Grade 0-1 from adverse events related to prior anticancer therapy&#xD;
                  except alopecia, ≤ Grade 2 sensory neuropathy, lymphopenia, and endocrinopathies&#xD;
                  controlled with hormone replacement therapy.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  1) Patient has primary light chain amyloidosis or plasma cell leukemia;&#xD;
&#xD;
             2) Patient has symptomatic central nervous system involvement of multiple myeloma;&#xD;
&#xD;
             3) Received systemic anti-myeloma therapy within 2 weeks, or received plasma exchange&#xD;
             within 4 weeks;&#xD;
&#xD;
             4) Received any experimental drugs within 4 weeks or 5 half-lives (whichever is&#xD;
             shorter);&#xD;
&#xD;
             5) Patient has received ≥ 40 mg/day dexamethasone equivalent within 7 days before&#xD;
             starting F182112. Short term use of corticosteroids at doses equivalent to &gt; 10 mg/d&#xD;
             of prednisone；&#xD;
&#xD;
             6) Received any monoclonal antibody therapy within 30 days;&#xD;
&#xD;
             7) Prior treatment with any B cell maturation antigen (BCMA) targeted therapy;&#xD;
&#xD;
             8) Patient had a prior allogeneic stem cell transplant or had a prior autologous stem&#xD;
             cell transplant ≤ 3 months prior to starting F182112;&#xD;
&#xD;
             9) Live virus vaccine within 30 days prior to study entry;&#xD;
&#xD;
             10) Major surgery within 4 weeks prior to study entry;&#xD;
&#xD;
             11) Concurrent malignancy within 3 years prior to entry other than adequately treated&#xD;
             cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell&#xD;
             carcinoma, prostate cancer under active surveillance, prostate cancer that has&#xD;
             undergone definitive treatment, ductal carcinoma in situ of the breast, or ≤ T1&#xD;
             urothelial carcinoma;&#xD;
&#xD;
             12) Patients with active mucosa or visceral bleeding;&#xD;
&#xD;
             13) Severe cardiovascular disease, including CVA, TIA, myocardial infarction, or&#xD;
             unstable angina within 6 months of study entry; NYHA class III or IV heart failure&#xD;
             within 6 months of study entry; Uncontrolled arrhythmia within 6 months of study&#xD;
             entry. Patients with a rate-controlled arrhythmia may be eligible for study entry at&#xD;
             the discretion of the Medical Monitor;&#xD;
&#xD;
             14) Active infection requiring antibiotic, antiviral or antifungul therapy;&#xD;
&#xD;
             15) Active viral hepatitis;&#xD;
&#xD;
             16) Has a history of immunodeficiency, include HIV infection;&#xD;
&#xD;
             17) Treponema pallidum infection;&#xD;
&#xD;
             18) Received any experimental drugs or anti-tumor drugs within 2 weeks;&#xD;
&#xD;
             19) Subject has any condition that confounds the ability to interpret data from the&#xD;
             study;&#xD;
&#xD;
             20) Females and males must practice true abstinence or agree to contraceptive methods&#xD;
             throughout the study, and 6 months after the last giving F182112;&#xD;
&#xD;
             21) Any condition that the investigator or primary physician believes may not be&#xD;
             appropriate for participating the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shaohong Yin</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaohong Yin</last_name>
      <phone>86-15265901803</phone>
      <email>yinshaohong@lunan.com.cn</email>
    </contact>
    <investigator>
      <last_name>JunYuan Qi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

